Because of aGvHD results I'm more optimistic of success in other trials.
One reason is the likely mechanism that the cells start off a healing process (rather than become anything). If this is the case, then that process could apply to any organ. It may just take longer in an avascular environment like the spine or a complex organ like the heart.
The other reason is a clear jump in efficacy I noticed in Hare et al's work, the latest study (that I'm aware of) published at the beginning of 2017 comparing auto- with allo- mscs in a group accounting for a large percentage of heart transplants. I wondered if these results were due to access to new technology (CRISPR?)
If I recall right, in the webcast on the recent aGvHD results, SI said in answer to a comment on improved results that in the past couple years MSB had had access to new technology.
All IMO. GLTAH
MSB trading, page-557
-
- There are more pages in this discussion • 2,908 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |